Summary of GKRS based series for meningioma treatment
| Author | No. of patients | Follow up, range (median) | Tumour volume (cm3),range (median) | Marginal dose (Gy),range (median) | Tumour control rate (%) | Comp (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N/A, data not available in the publication. Comp, complications. | ||||||||||||
| Kondziolka29 | 50 | 6 to 34 (N/A) | N/A | 10 to 25(16.7) | 96 | 6 | ||||||
| Duma21 | 34 | 6 to 54 (26) | 0.5 to 20.4 (5.17) | 10 to 20 (16) | 100 | 20 | ||||||
| Ganz49 | 20 | 12 to 27 (N/A) | N/A | 5.1 to 28.5 (N/A) | 80 | 0 | ||||||
| Nikolato48 | 50 | 4 to 31 (14) | 0.6 to 20 (8.6) | 10 to 28 (18) | 98 | 6 | ||||||
| Liscak23 | 53 | 2 to 60 (19) | 0.9 to 31.4 (7.8) | 10 to 14 (12) | 100 | 13 | ||||||
| Iwai22 | 24 | 6 to 36 (17.1) | 0.1 to 28.6 (11) | 8 to 15 (10.6) | 100 | 4 | ||||||
| Morita50 | 88 | 12 to 83 (35) | N/A (10) | 12 to 20 (16) | 98 | 14.8 | ||||||
| Nakaya46 | 11 | 21 to 57 (35.7) | 1.6 to 28.9 (7.1) | 9.9 to 10 (10) | 100 | 9 | ||||||
| Kondziolka16 | 99 | 60 to 120 (N/A) | 0.24 to 24 (4.7) | 9 to 25 (16) | 93 | 13 | ||||||
| Aichholzer14 | 46 | 36 to 76 (48) | N/A | 9 to 25 (15.9) | 97.5 | 4.3 | ||||||
| Pendl32 | 164 | 25 to 97 (55) | 0.5 to 89.9 (8.3) | 7 to 25 (12) | 98 | 1.8 | ||||||
| Kobayashi47 | 54 | 60 to 108 (84) | N/A | N/A (14.5) | 89 | 5.5 (?) | ||||||
| Eustacchio15 | 121 | 60 to 117 (82) | 0.5 to 89.9 (6.8) | 7 to 25 (13) | 98.3 | 3.3 | ||||||
| Current study | 200 | 60 to 144 (95) | 0.38 to 89.9 (6.5) | 7 to 25 (12) | 97.5 | 2.5 | ||||||